Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: Results of a large prospective study

Marilyn F. Dille, Dawn Konrad-Martin, Frederick Gallun, Wendy J. Helt, Jane S. Gordon, Kelly M. Reavis, Gene W. Bratt, Stephen A. Fausti

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background and Purpose: To report on the incidence and relative risk of tinnitus onset from a variety of drug therapies known to be ototoxic. Two main questions were asked: (1) What is the prevalence and incidence of tinnitus among patients treated with cisplatin, carboplatin, or ototoxic antibiotic therapies? (2) Do commonly reported treatment or subject factors confound or modify the incidence of tinnitus onset? Data Collection and Analysis: A prospective observational study design was used to evaluate occurrence of significant otologic changes in 488 veterans (962 ears) receiving chemotherapeutic agents (cisplatin, carboplatin), ototoxic antibiotics (primarily aminoglycoside), or nonototoxic drugs (control medications). A subset of 260 veterans lacking tinnitus prior to drug exposure was used to compare rates of tinnitus onset. Subjects were tested prior to, during, and following their treatment. Planned comparisons using logistic regression, analysis of variance (ANOVA), and χ2 statistics were made among groups by the type of medication taken, age, presence of preexisting hearing loss, days on drug, and cumulative dose of drug. Results: Baseline tinnitus rates were high (nearly 47%) relative to the general population of a similar age. Subjects with exposure to ototoxic medications had significantly increased risk for developing tinnitus. Those on chemotherapeutic agents were found to have the greatest risk. Cisplatin elevated the risk by 5.53 times while carboplatin increased the risk by 3.75 over nonototoxic control medications. Ototoxic antibiotics resulted in borderline risk (2.81) for new tinnitus. Contrary to other reports, we did not find that subject factors (increased age or pre-existing hearing loss) or treatment factors (days on drug or cumulative dose) contributed to rates of tinnitus onset during treatment. Conclusions: This large prospective study confirms that new tinnitus during treatment is associated with chemotherapy and with certain ototoxic antibiotic treatment. Cisplatin and carboplatin were found to be the most potent ototoxic agents causing tinnitus at much greater numbers than the other drugs studied. Implications for counseling and audiological resource allocation are discussed.

Original languageEnglish (US)
Pages (from-to)409-417
Number of pages9
JournalJournal of the American Academy of Audiology
Volume21
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Tinnitus
Prospective Studies
Anti-Bacterial Agents
Carboplatin
Cisplatin
Pharmaceutical Preparations
Veterans
Hearing Loss
Therapeutics
Incidence
Drug Therapy
Resource Allocation
Drug and Narcotic Control
Age Factors
Aminoglycosides
Observational Studies
Ear
Counseling
Analysis of Variance
Logistic Models

Keywords

  • Ototoxicity
  • Ototoxicity monitoring
  • Tinnitus
  • Veterans

ASJC Scopus subject areas

  • Speech and Hearing
  • Medicine(all)

Cite this

Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics : Results of a large prospective study. / Dille, Marilyn F.; Konrad-Martin, Dawn; Gallun, Frederick; Helt, Wendy J.; Gordon, Jane S.; Reavis, Kelly M.; Bratt, Gene W.; Fausti, Stephen A.

In: Journal of the American Academy of Audiology, Vol. 21, No. 6, 06.2010, p. 409-417.

Research output: Contribution to journalArticle

Dille, Marilyn F. ; Konrad-Martin, Dawn ; Gallun, Frederick ; Helt, Wendy J. ; Gordon, Jane S. ; Reavis, Kelly M. ; Bratt, Gene W. ; Fausti, Stephen A. / Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics : Results of a large prospective study. In: Journal of the American Academy of Audiology. 2010 ; Vol. 21, No. 6. pp. 409-417.
@article{3733709b097a459d9a68c88513182e56,
title = "Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: Results of a large prospective study",
abstract = "Background and Purpose: To report on the incidence and relative risk of tinnitus onset from a variety of drug therapies known to be ototoxic. Two main questions were asked: (1) What is the prevalence and incidence of tinnitus among patients treated with cisplatin, carboplatin, or ototoxic antibiotic therapies? (2) Do commonly reported treatment or subject factors confound or modify the incidence of tinnitus onset? Data Collection and Analysis: A prospective observational study design was used to evaluate occurrence of significant otologic changes in 488 veterans (962 ears) receiving chemotherapeutic agents (cisplatin, carboplatin), ototoxic antibiotics (primarily aminoglycoside), or nonototoxic drugs (control medications). A subset of 260 veterans lacking tinnitus prior to drug exposure was used to compare rates of tinnitus onset. Subjects were tested prior to, during, and following their treatment. Planned comparisons using logistic regression, analysis of variance (ANOVA), and χ2 statistics were made among groups by the type of medication taken, age, presence of preexisting hearing loss, days on drug, and cumulative dose of drug. Results: Baseline tinnitus rates were high (nearly 47{\%}) relative to the general population of a similar age. Subjects with exposure to ototoxic medications had significantly increased risk for developing tinnitus. Those on chemotherapeutic agents were found to have the greatest risk. Cisplatin elevated the risk by 5.53 times while carboplatin increased the risk by 3.75 over nonototoxic control medications. Ototoxic antibiotics resulted in borderline risk (2.81) for new tinnitus. Contrary to other reports, we did not find that subject factors (increased age or pre-existing hearing loss) or treatment factors (days on drug or cumulative dose) contributed to rates of tinnitus onset during treatment. Conclusions: This large prospective study confirms that new tinnitus during treatment is associated with chemotherapy and with certain ototoxic antibiotic treatment. Cisplatin and carboplatin were found to be the most potent ototoxic agents causing tinnitus at much greater numbers than the other drugs studied. Implications for counseling and audiological resource allocation are discussed.",
keywords = "Ototoxicity, Ototoxicity monitoring, Tinnitus, Veterans",
author = "Dille, {Marilyn F.} and Dawn Konrad-Martin and Frederick Gallun and Helt, {Wendy J.} and Gordon, {Jane S.} and Reavis, {Kelly M.} and Bratt, {Gene W.} and Fausti, {Stephen A.}",
year = "2010",
month = "6",
doi = "10.3766/jaaa.21.6.6",
language = "English (US)",
volume = "21",
pages = "409--417",
journal = "Journal of the American Academy of Audiology",
issn = "1050-0545",
publisher = "American Academy of Audiology",
number = "6",

}

TY - JOUR

T1 - Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics

T2 - Results of a large prospective study

AU - Dille, Marilyn F.

AU - Konrad-Martin, Dawn

AU - Gallun, Frederick

AU - Helt, Wendy J.

AU - Gordon, Jane S.

AU - Reavis, Kelly M.

AU - Bratt, Gene W.

AU - Fausti, Stephen A.

PY - 2010/6

Y1 - 2010/6

N2 - Background and Purpose: To report on the incidence and relative risk of tinnitus onset from a variety of drug therapies known to be ototoxic. Two main questions were asked: (1) What is the prevalence and incidence of tinnitus among patients treated with cisplatin, carboplatin, or ototoxic antibiotic therapies? (2) Do commonly reported treatment or subject factors confound or modify the incidence of tinnitus onset? Data Collection and Analysis: A prospective observational study design was used to evaluate occurrence of significant otologic changes in 488 veterans (962 ears) receiving chemotherapeutic agents (cisplatin, carboplatin), ototoxic antibiotics (primarily aminoglycoside), or nonototoxic drugs (control medications). A subset of 260 veterans lacking tinnitus prior to drug exposure was used to compare rates of tinnitus onset. Subjects were tested prior to, during, and following their treatment. Planned comparisons using logistic regression, analysis of variance (ANOVA), and χ2 statistics were made among groups by the type of medication taken, age, presence of preexisting hearing loss, days on drug, and cumulative dose of drug. Results: Baseline tinnitus rates were high (nearly 47%) relative to the general population of a similar age. Subjects with exposure to ototoxic medications had significantly increased risk for developing tinnitus. Those on chemotherapeutic agents were found to have the greatest risk. Cisplatin elevated the risk by 5.53 times while carboplatin increased the risk by 3.75 over nonototoxic control medications. Ototoxic antibiotics resulted in borderline risk (2.81) for new tinnitus. Contrary to other reports, we did not find that subject factors (increased age or pre-existing hearing loss) or treatment factors (days on drug or cumulative dose) contributed to rates of tinnitus onset during treatment. Conclusions: This large prospective study confirms that new tinnitus during treatment is associated with chemotherapy and with certain ototoxic antibiotic treatment. Cisplatin and carboplatin were found to be the most potent ototoxic agents causing tinnitus at much greater numbers than the other drugs studied. Implications for counseling and audiological resource allocation are discussed.

AB - Background and Purpose: To report on the incidence and relative risk of tinnitus onset from a variety of drug therapies known to be ototoxic. Two main questions were asked: (1) What is the prevalence and incidence of tinnitus among patients treated with cisplatin, carboplatin, or ototoxic antibiotic therapies? (2) Do commonly reported treatment or subject factors confound or modify the incidence of tinnitus onset? Data Collection and Analysis: A prospective observational study design was used to evaluate occurrence of significant otologic changes in 488 veterans (962 ears) receiving chemotherapeutic agents (cisplatin, carboplatin), ototoxic antibiotics (primarily aminoglycoside), or nonototoxic drugs (control medications). A subset of 260 veterans lacking tinnitus prior to drug exposure was used to compare rates of tinnitus onset. Subjects were tested prior to, during, and following their treatment. Planned comparisons using logistic regression, analysis of variance (ANOVA), and χ2 statistics were made among groups by the type of medication taken, age, presence of preexisting hearing loss, days on drug, and cumulative dose of drug. Results: Baseline tinnitus rates were high (nearly 47%) relative to the general population of a similar age. Subjects with exposure to ototoxic medications had significantly increased risk for developing tinnitus. Those on chemotherapeutic agents were found to have the greatest risk. Cisplatin elevated the risk by 5.53 times while carboplatin increased the risk by 3.75 over nonototoxic control medications. Ototoxic antibiotics resulted in borderline risk (2.81) for new tinnitus. Contrary to other reports, we did not find that subject factors (increased age or pre-existing hearing loss) or treatment factors (days on drug or cumulative dose) contributed to rates of tinnitus onset during treatment. Conclusions: This large prospective study confirms that new tinnitus during treatment is associated with chemotherapy and with certain ototoxic antibiotic treatment. Cisplatin and carboplatin were found to be the most potent ototoxic agents causing tinnitus at much greater numbers than the other drugs studied. Implications for counseling and audiological resource allocation are discussed.

KW - Ototoxicity

KW - Ototoxicity monitoring

KW - Tinnitus

KW - Veterans

UR - http://www.scopus.com/inward/record.url?scp=77956580729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956580729&partnerID=8YFLogxK

U2 - 10.3766/jaaa.21.6.6

DO - 10.3766/jaaa.21.6.6

M3 - Article

C2 - 20701838

AN - SCOPUS:77956580729

VL - 21

SP - 409

EP - 417

JO - Journal of the American Academy of Audiology

JF - Journal of the American Academy of Audiology

SN - 1050-0545

IS - 6

ER -